- Home
- GANX vs NTRB Comparison
GANX vs NTRB Comparison
Compare GANX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- NTRB
- Stock Information
- Founded
- GANX 2017
- NTRB 2016
- Country
- GANX United States
- NTRB United States
- Employees
- GANX N/A
- NTRB N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- GANX Health Care
- NTRB Health Care
- Exchange
- GANX Nasdaq
- NTRB Nasdaq
- Market Cap
- GANX 53.8M
- NTRB 59.1M
- IPO Year
- GANX 2021
- NTRB N/A
- Fundamental
- Price
- GANX $1.77
- NTRB $7.50
- Analyst Decision
- GANX Strong Buy
- NTRB Buy
- Analyst Count
- GANX 5
- NTRB 1
- Target Price
- GANX $8.20
- NTRB $13.00
- AVG Volume (30 Days)
- GANX 247.1K
- NTRB 82.0K
- Earning Date
- GANX 08-07-2025
- NTRB 05-30-2025
- Dividend Yield
- GANX N/A
- NTRB N/A
- EPS Growth
- GANX N/A
- NTRB N/A
- EPS
- GANX N/A
- NTRB N/A
- Revenue
- GANX N/A
- NTRB $2,398,437.00
- Revenue This Year
- GANX N/A
- NTRB $560.75
- Revenue Next Year
- GANX N/A
- NTRB $588.39
- P/E Ratio
- GANX N/A
- NTRB N/A
- Revenue Growth
- GANX N/A
- NTRB 18.92
- 52 Week Low
- GANX $0.89
- NTRB $3.72
- 52 Week High
- GANX $3.19
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- GANX 44.69
- NTRB 59.79
- Support Level
- GANX $1.85
- NTRB $7.00
- Resistance Level
- GANX $1.81
- NTRB $7.90
- Average True Range (ATR)
- GANX 0.15
- NTRB 0.66
- MACD
- GANX -0.01
- NTRB -0.01
- Stochastic Oscillator
- GANX 32.61
- NTRB 37.45
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.